Ulcerative Colitis.
A clinician-facing, evidence-anchored resource on ulcerative colitis — from Montreal extent and Truelove–Witts severity through medical escalation to the point where surgery enters the picture: acute severe colitis, colectomy, and staged restorative proctocolectomy with an ileal pouch.
Grading a flare
The Truelove–Witts index remains the bedside anchor for classifying UC activity. Its “severe” category defines acute severe ulcerative colitis (ASUC) — the threshold for admission, intravenous steroids, and a surgical consult.
| Feature | Mild | Moderate | Severe (ASUC) |
|---|---|---|---|
| Clinical | |||
| Bloody stools/day | <4 | 4–6 | ≥6 |
| Blood in stool | Small | Moderate | Visible, frequent |
| Systemic | |||
| Temperature | Apyrexial | Intermediate | >37.8 °C |
| Pulse | <90 bpm | Intermediate | >90 bpm |
| Laboratory | |||
| Hemoglobin | Normal | Intermediate | ≤10.5 g/dL |
| ESR | ≤30 mm/h | Intermediate | >30 mm/h |
| CRP | Normal | Mildly raised | >30 mg/L* |
* CRP is a modern addition to the original 1955 criteria. ASUC = Truelove–Witts severe: ≥6 bloody stools/day plus at least one systemic sign (fever, tachycardia, anemia, or raised ESR/CRP). Endoscopic severity is scored separately by the Mayo endoscopic subscore or the UCEIS. Disease extent follows the Montreal system: E1 proctitis, E2 left-sided, E3 extensive (pancolitis).
Frequently Asked Questions
Quick, plain-language answers to the questions we hear most.
What defines acute severe ulcerative colitis (ASUC)?
ASUC is defined by the Truelove & Witts severe criteria: six or more bloody stools per day plus at least one marker of systemic toxicity — temperature >37.8 °C, heart rate >90 bpm, hemoglobin ≤10.5 g/dL, or ESR >30 mm/h (CRP is a common modern surrogate). It is a medical emergency requiring admission, intravenous corticosteroids, VTE prophylaxis, and early surgical involvement. Roughly a third of episodes fail steroids and need rescue therapy or colectomy.
When is colectomy indicated in ulcerative colitis?
Broadly in four settings: medically refractory disease, acute severe colitis failing medical rescue, colitis-associated dysplasia or cancer, and emergencies such as toxic megacolon, perforation, or uncontrolled hemorrhage. Emergency colectomy is life-saving; elective colectomy is a quality-of-life and cancer-prevention decision made electively. The ASCRS clinical practice guidelines detail the indications and operative strategy.
What is the timing of surgery in ASUC that fails rescue therapy?
Response to intravenous steroids is assessed by day 3; non-responders are offered medical rescue (infliximab or ciclosporin) or colectomy. If rescue therapy does not produce clear improvement within about 5–7 days, colectomy should not be delayed — protracted salvage attempts increase perioperative morbidity. The ciclosporin-versus-infliximab trial found the two rescue agents comparable, so the choice hinges on local expertise and patient factors.
What are the staged approaches to restorative proctocolectomy?
There are three common pathways. The three-stage approach (subtotal colectomy with end ileostomy, then completion proctectomy with IPAA and a diverting loop ileostomy, then ileostomy closure) is standard after emergency presentation or when the patient is malnourished or on high-dose steroids or biologics. The two-stage approach (proctocolectomy with IPAA and diverting ileostomy, then closure) suits well-optimized elective patients. The modified two-stage (subtotal colectomy with end ileostomy first, then completion proctectomy with pouch but no diverting ileostomy) spreads the risk of the acute presentation while sparing a third operation.
Who is a candidate for an ileal pouch-anal anastomosis (IPAA)?
Good candidates have confirmed ulcerative colitis (or IBD-unclassified) rather than Crohn’s disease, adequate anal sphincter function and continence, and no low rectal cancer requiring wide excision. Older age and obesity raise complication rates but are not absolute contraindications. Counseling should cover expected function, pouchitis, and fertility, since a pouch is a quality-of-life operation — large series report durable pouch survival and good quality of life in the great majority.
What is pouchitis and how common is it?
Pouchitis is non-specific inflammation of the ileal pouch and the most common long-term complication of IPAA, affecting up to roughly half of patients at some point. Most acute episodes respond to a short antibiotic course (metronidazole or ciprofloxacin); a minority develop chronic antibiotic-dependent or antibiotic-refractory disease. The AGA pouchitis guideline outlines a stepwise approach through probiotics, chronic antibiotics, and advanced immunosuppression.
How does dysplasia and colorectal-cancer surveillance work in UC?
Surveillance colonoscopy typically begins about 8 years after symptom onset (earlier and more often with concurrent primary sclerosing cholangitis), then continues at intervals stratified by cumulative risk — extent, inflammation burden, family history, and prior dysplasia. The SCENIC consensus endorses high-definition colonoscopy with chromoendoscopy and targeted biopsy of visible lesions. Cumulative cancer risk rises with disease duration — a classic meta-analysis estimated roughly 2% at 10 years, 8% at 20, and 18% at 30 years.
When is colectomy indicated for dysplasia in UC?
Total proctocolectomy is standard for high-grade dysplasia and for endoscopically unresectable or invisible (flat) dysplasia, given the substantial risk of synchronous or metachronous cancer. Visible, well-circumscribed dysplastic lesions that are completely resected endoscopically may be managed with intensified surveillance in selected patients. Any confirmed colitis-associated cancer mandates an oncologic proctocolectomy.
Does an ileal pouch affect fertility?
Yes — pelvic dissection can cause adhesions around the fallopian tubes and ovaries, and a meta-analysis found roughly a threefold increase in infertility after ileal pouch surgery compared with medical management. This should be discussed before surgery with women who may wish to conceive. A minimally invasive technique, and in selected cases deferring the pouch or considering an ileorectal anastomosis, can mitigate the risk.
Extent, Activity, and the ASUC Threshold
Two axes drive management in ulcerative colitis: how much colon is involved (extent) and how active the inflammation is (severity). Together they set the medical ceiling and flag the patients who cross into surgical territory.
Montreal extent (E1–E3)
E1 ulcerative proctitis, E2 left-sided colitis (distal to the splenic flexure), E3 extensive colitis (proximal to the splenic flexure, including pancolitis). Extent predicts colorectal-cancer risk, surveillance intervals, and the likelihood of eventual colectomy.
Severity indices
Truelove–Witts grades clinical activity at the bedside; the Mayo score combines stool frequency, rectal bleeding, endoscopy, and physician global assessment; the UCEIS standardizes endoscopic severity. Each anchors escalation decisions and trial endpoints.
Acute severe UC (ASUC)
Defined by the Truelove–Witts severe criteria — ≥6 bloody stools/day plus a systemic sign. ASUC is a medical emergency requiring admission, intravenous corticosteroids, VTE prophylaxis, and early involvement of a colorectal surgeon.
Extent-driven implications
Extensive, long-standing colitis carries the highest cumulative cancer risk and the strongest case for structured dysplasia surveillance — and, when disease is refractory, for definitive surgery rather than open-ended medical cycling.
Classification & severity — key references
Every reference below has been verified against PubMed and links directly to its record. This digest is educational and does not replace clinical judgement or society guidelines.
Extent & phenotype
The Montreal classification standardized how UC extent (E1–E3) and IBD phenotype are recorded, replacing ad-hoc descriptors and enabling comparison across cohorts and trials.
- Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19 Suppl A:5A-36A. PMID 16151544
- Ordás I, Eckmann L, Talamini M, et al. Ulcerative colitis. Lancet. 2012;380(9853):1606-19. PMID 22914296
Severity indices
The Truelove–Witts criteria (1955) remain the operational definition of acute severe UC. The Mayo Clinic score — introduced in Schroeder’s 1987 mesalamine trial — and the UCEIS refined clinical and endoscopic scoring, respectively.
- Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J. 1955;2(4947):1041-8. PMID 13260656
- Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317(26):1625-9. PMID 3317057
- Travis SP, Schnell D, Krzeski P, et al. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut. 2012;61(4):535-42. PMID 21997563
This digest is educational and does not replace clinical judgement or society guidelines.
Escalation and the Medical–Surgical Decision Point
Medical management follows a step-up ladder from aminosalicylates to advanced therapies, with the goal of steroid-free remission and mucosal healing. The clinically decisive moment is when a patient exhausts or fails medical options — that is where the surgical conversation begins.
5-ASA (aminosalicylates)
First-line induction and maintenance for mild-to-moderate disease, oral and topical. Effective for proctitis and left-sided disease; combination oral-plus-rectal dosing improves response. Little role in severe disease or as maintenance after biologics.
Corticosteroids
Rapidly control active flares but are not maintenance agents. Steroid dependence or refractoriness is itself an indication to escalate. Intravenous steroids are the backbone of acute severe UC management.
Thiopurines
Azathioprine and 6-mercaptopurine provide steroid-sparing maintenance, often in combination with anti-TNF therapy to reduce immunogenicity. Slow onset limits their use for induction.
Anti-TNF (infliximab)
The first biologic proven for UC induction and maintenance, and a standard rescue agent in acute severe disease. Therapeutic drug monitoring and dose optimization sustain response.
Other advanced therapies
Vedolizumab (gut-selective anti-integrin), ustekinumab (anti-IL-12/23), and the oral small molecules tofacitinib and upadacitinib (JAK inhibitors) expand options for anti-TNF–exposed or refractory patients.
ASUC rescue therapy
Steroid non-responders by day 3 receive rescue with infliximab or ciclosporin. The two are comparable; the choice is driven by expertise and comorbidity. Failure of rescue is a hard indication for colectomy.
Medical therapy & escalation — key references
Landmark trials and guidelines behind the escalation ladder, each verified against PubMed. The label matters most at the point of surgical decision-making, where the surgical section takes over.
Guideline-based management
Contemporary guidelines integrate aminosalicylates, corticosteroids, thiopurines, and advanced therapies into a step-up algorithm keyed to disease extent and severity.
- Rubin DT, Ananthakrishnan AN, Siegel CA, et al. ACG Clinical Guideline: Ulcerative Colitis in Adults. Am J Gastroenterol. 2019;114(3):384-413. PMID 30840605
Biologics & small molecules
Registration trials established anti-TNF, anti-integrin, anti-IL-12/23, and JAK-inhibitor therapy for moderate-to-severe UC, progressively expanding options after 5-ASA and steroid failure.
- Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462-76. PMID 16339095
- Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369(8):699-710. PMID 23964932
- Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376(18):1723-1736. PMID 28467869
- Sands BE, Sandborn WJ, Panaccione R, et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2019;381(13):1201-1214. PMID 31553833
Acute severe UC rescue therapy
In intravenous-steroid–refractory ASUC, infliximab and ciclosporin achieve comparable rates of avoiding early colectomy; failure of rescue is a hard indication for surgery.
- Laharie D, Bourreille A, Branche J, et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet. 2012;380(9857):1909-15. PMID 23063316
- Williams JG, Alam MF, Alrubaiy L, et al. Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial. Lancet Gastroenterol Hepatol. 2016;1(1):15-24. PMID 27595142
This digest is educational and does not replace clinical judgement or society guidelines.
Colectomy, Staged IPAA, and Cancer Prevention
Surgery is curative of the colonic disease in ulcerative colitis. The decisions that matter are when to operate, which operation and how many stages, and how to counsel on the long-term trade-offs of an ileal pouch. Emergency and elective pathways diverge sharply.
Indications for colectomy
Medically refractory disease, acute severe colitis failing rescue, dysplasia or colorectal cancer, and emergencies — toxic megacolon, perforation, or uncontrolled hemorrhage. Emergency indications are life-saving; elective ones weigh quality of life and cancer prevention.
Emergency surgery
The safe emergency operation is subtotal (total abdominal) colectomy with end ileostomy, leaving the rectal stump. It removes the diseased colon, permits pathologic review, and defers the pelvic dissection until the patient is optimized off steroids and biologics.
Staged restorative proctocolectomy (IPAA)
Restoration uses an ileal pouch-anal anastomosis. The three-stage approach follows emergency colectomy; the two-stage (proctocolectomy + IPAA + diverting ileostomy → closure) suits optimized elective patients; the modified two-stage (subtotal colectomy first, then pouch without diversion) spreads risk while sparing a third operation.
IPAA candidacy & counseling
Candidacy requires confirmed UC (not Crohn’s), adequate sphincter function, and no low rectal cancer needing wide excision. Counseling covers expected pouch function, the high lifetime rate of pouchitis, and the female fertility impact of pelvic dissection.
Dysplasia & cancer surveillance
Surveillance colonoscopy from ~8 years after onset (earlier with PSC), at risk-stratified intervals, using high-definition endoscopy with chromoendoscopy and targeted biopsy of visible lesions per the SCENIC consensus.
Colectomy for dysplasia
Total proctocolectomy is standard for high-grade dysplasia and for invisible or unresectable dysplasia given the synchronous-cancer risk. Completely resected visible lesions may be surveilled in selected patients; confirmed cancer mandates oncologic proctocolectomy.
Surgery, IPAA & surveillance — key references
The surgical evidence base — society guidelines, pouch-outcome series, and dysplasia-surveillance consensus — each reference verified against PubMed. For the Crohn’s surgical hub see Crohnsology.org.
Guidelines & indications
Society guidelines codify the indications for colectomy, the choice of staged restorative versus non-restorative surgery, and the sequencing of operations in acute and elective settings.
- Holubar SD, Lightner AL, Poylin V, et al. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Surgical Management of Ulcerative Colitis. Dis Colon Rectum. 2021;64(7):783-804. PMID 33853087
- Øresland T, Bemelman WA, Sampietro GM, et al. European evidence based consensus on surgery for ulcerative colitis. J Crohns Colitis. 2015;9(1):4-25. PMID 25304060
IPAA outcomes & counseling
Large series document durable pouch survival and good quality of life after IPAA; pouchitis is the most common long-term complication, and pelvic dissection reduces female fertility — both central to informed consent.
- Fazio VW, Kiran RP, Remzi FH, et al. Ileal pouch anal anastomosis: analysis of outcome and quality of life in 3707 patients. Ann Surg. 2013;257(4):679-85. PMID 23299522
- Barnes EL, Agrawal M, Syal G, et al. AGA Clinical Practice Guideline on the Management of Pouchitis and Inflammatory Pouch Disorders. Gastroenterology. 2024;166(1):59-85. PMID 38128971
- Waljee A, Waljee J, Morris AM, et al. Threefold increased risk of infertility: a meta-analysis of infertility after ileal pouch anal anastomosis in ulcerative colitis. Gut. 2006;55(11):1575-80. PMID 16772310
Dysplasia & cancer surveillance
Cumulative colorectal-cancer risk rises with colitis duration and extent; structured surveillance with chromoendoscopy and targeted biopsy guides the decision between intensified follow-up and colectomy.
- Laine L, Kaltenbach T, Barkun A, et al. SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease. Gastroenterology. 2015;148(3):639-651.e28. PMID 25702852
- Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48(4):526-35. PMID 11247898
This digest is educational and does not replace clinical judgement or society guidelines.
AI-powered UC surgical evidence — coming soon
We are building a searchable, askable corpus of the ulcerative-colitis surgical and high-acuity literature — acute severe UC, colectomy, and restorative proctocolectomy with IPAA — so clinicians can query titles, abstracts, and full text in one place. Until it launches, explore the evidence-anchored clinical summaries across this site, or the broader IBD literature across the IBDology family.
About UColitis.org
UColitis.org is a clinician- and trainee-facing evidence resource for ulcerative colitis, with a deliberate surgical emphasis — classification and severity, medical escalation, acute severe UC, colectomy indications, and staged restorative proctocolectomy with an ileal pouch. It offers concise, evidence-anchored digests (every reference verified against PubMed), with an AI-powered evidence explorer and living leaderboards of the UC literature coming soon. It is the surgical companion in the IBDology family of sites: for Crohn’s surgical decision-making see Crohnsology.org, for IBD with primary sclerosing cholangitis see IBD-PSC.org, for colitis that defies the UC/Crohn’s label see IBDunclassified.org, and for the family overview see IBDology.org.
This site was created by Stefan D. Holubar, MD, MS, FACS, FASCRS, Professor of Surgery at Cleveland Clinic and the Cleveland Clinic Lerner College of Medicine & Case Western Reserve University. A fellowship-trained colorectal surgeon who specializes in inflammatory bowel disease—and, living with IBD and a J-pouch himself, a patient too—he brings both perspectives to this work. He is co-PI of the Crohn's & Colitis Foundation IBD-SIRCQ and the ACS-NSQIP IBD Collaborative, founder of the iPouch Consortium, and has authored over 300 peer-reviewed publications.
Dr. Holubar is an employee of Cleveland Clinic, and has the following disclosures: research funding from the American Society of Colon & Rectal Surgeons and the Crohn's & Colitis Foundation, and has no other disclosures or conflicts of interest.